(Q45254298)

English

Consideration of the use of 17?-N,N-diethylcarbamoyl-4-methyl-4-aza-5-?-androstan-3-one (4MA), a 5?-reductase inhibitor, in prostate cancer therapy

scientific article published on January 1, 1992

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

11 December 2017

Consideration of the use of 17?-N,N-diethylcarbamoyl-4-methyl-4-aza-5-?-androstan-3-one (4MA), a 5?-reductase inhibitor, in prostate cancer therapy (English)

reason for preferred rank

most precise value

1 reference

10.1007/BF01192311

https://api.crossref.org/works/10.1007/BF01192311

10 November 2022

Consideration of the use of 17 beta-N,N-diethylcarbamoyl-4-methyl-4-aza-5- alpha-androstan-3-one (4MA), a 5 alpha-reductase inhibitor, in prostate cancer therapy (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1729259

10 November 2022

1 reference

10.1007/BF01192311

https://api.crossref.org/works/10.1007/BF01192311

10 November 2022

author name string

A. A. Geldof

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1729259

10 November 2022

M. F. Meulenbroek

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1729259

10 November 2022

I. Dijkstra

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1729259

10 November 2022

S. Bohlken

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1729259

10 November 2022

B. R. Rao

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1729259

10 November 2022

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 January 1992

1 reference

Europe PubMed Central

11 December 2017

full work available at URL

http://link.springer.com/content/pdf/10.1007/BF01192311.pdf

Portable Document Format

1 reference

10.1007/BF01192311

https://api.crossref.org/works/10.1007/BF01192311

10 November 2022

http://link.springer.com/article/10.1007/BF01192311/fulltext.html

1 reference

10.1007/BF01192311

https://api.crossref.org/works/10.1007/BF01192311

10 November 2022

http://link.springer.com/content/pdf/10.1007/BF01192311

1 reference

10.1007/BF01192311

https://api.crossref.org/works/10.1007/BF01192311

10 November 2022

Journal of Cancer Research and Clinical Oncology

1 reference

Europe PubMed Central

11 December 2017

118

1 reference

Europe PubMed Central

11 December 2017

1

1 reference

Europe PubMed Central

11 December 2017

50-55

1 reference

Europe PubMed Central

11 December 2017

https://scigraph.springernature.com/pub.10.1007/bf01192311

0 references

Retardation of prostate tumor progression in the Noble rat by 4-methyl-4-aza-steroidal inhibitors of 5 alpha-reductase

1 reference

https://pubmed.ncbi.nlm.nih.gov/1729259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of prostatic cancer tissue dihydrotestosterone levels at the time of relapse following orchiectomy or estrogen therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/1729259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Response of Rat Ventral Prostate to a New and Novel 5αa-Reductase Inhibitor

1 reference

https://pubmed.ncbi.nlm.nih.gov/1729259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combination of an antiandrogen and a 5 alpha-reductase inhibitor: a further step towards total androgen blockade?

1 reference

https://pubmed.ncbi.nlm.nih.gov/1729259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The effect of 4MA, a potent inhibitor of 5 alpha-reductase, on the growth of androgen-responsive human genitourinary tumors grown in athymic nude mice

1 reference

https://pubmed.ncbi.nlm.nih.gov/1729259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A prospective, population-based study of androstenedione, estrogens, and prostatic cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/1729259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

12. Androgens: Pharmacodynamics and antagonists. Biochemical and biological studies with 4-aza-steroidal 5 alpha-reductase inhibitors

1 reference

https://pubmed.ncbi.nlm.nih.gov/1729259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Direct effects of chemotherapeutic agents on rat prostate tumor clonogenic cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/1729259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Renewal timing of long-acting depot luteinizing hormone-releasing hormone agonist (Zoladex) is critical in the treatment of hormone-dependent rat prostatic carcinoma (R3327-H)

1 reference

https://pubmed.ncbi.nlm.nih.gov/1729259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and advantages in the use of low doses of anandron and estrogen combination in the treatment of prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/1729259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Binding of a 4-methyl-4-aza-steroid to 5 alpha-reductase of rat liver and prostate microsomes

1 reference

https://pubmed.ncbi.nlm.nih.gov/1729259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Steroid metabolism and binding in relation to prostatic cell growth and differentiation in vitro

1 reference

https://pubmed.ncbi.nlm.nih.gov/1729259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Biological activities of a new steroidal inhibitor of delta 4-5 alpha-reductase

1 reference

https://pubmed.ncbi.nlm.nih.gov/1729259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibition of 5 alpha-reductase, receptor binding, and nuclear uptake of androgens in the prostate by a 4-methyl-4-aza-steroid

1 reference

https://pubmed.ncbi.nlm.nih.gov/1729259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

New approach in the treatment of prostate cancer: complete instead of partial withdrawal of androgens

1 reference

https://pubmed.ncbi.nlm.nih.gov/1729259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Selective inhibition of prostatic tumor 5 alpha-reductase by a 4-methyl-4-azasteroid

1 reference

https://pubmed.ncbi.nlm.nih.gov/1729259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibitors of steroid 5 alpha-reductase in benign prostatic hyperplasia, male pattern baldness and acne

1 reference

https://pubmed.ncbi.nlm.nih.gov/1729259

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Journal of the National Cancer Institute

11

74

475

author name string

N Kadohama

publication date

1985

1 reference

10.1007/BF01192311

https://api.crossref.org/works/10.1007/BF01192311

10 November 2022

Identifiers

10.1007/BF01192311

1 reference

Europe PubMed Central

11 December 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

11 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45254298&oldid=1768460860"